Besponsa
Chemical Name | inotuzumab ozogamicin |
Dosage Form | Injectable (intravenous; 0.9 mg/vial) |
Drug Class | Monoclonal antibodies |
System | Blood |
Company | Wyeth Pharmaceuticals |
Approval Year | 2017 |
Indication
- Besponsa is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.